GlassScriptPhysician profile
Craig J Shapiro
NPI 1700824521
$57,362.81
in general payments reported to CMS, 2019-2025
31 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $2,945 · 2021: $16K · 2022: $6,704 · 2023: $24K · 2024: $7,169 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $3,132 · Travel and Lodging: $641 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,550.00 |
| Food and Beverage | $3,131.80 |
| Travel and Lodging | $640.88 |
| Education | $142.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $54,446.45 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $385.10 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $371.66 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $341.70 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $300.73 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $135.49 | 2020-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $125.33 | 2020-2023 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $117.07 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $106.95 | 2019 | |
| Amgen INC. | $103.23 | 2021-2025 | Krystexxa |
| Intuitive Surgical, INC. | $93.68 | 2025 | |
| Ardelyx, INC. | $87.55 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $83.17 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.99 | 2023-2025 | |
| Travere Therapeutics, INC. | $71.75 | 2023-2025 | Filspari |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $67.81 | 2025 | |
| Aurinia Pharma U.S., INC. | $62.85 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $52.89 | 2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $51.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.53 | 2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $46.55 | 2019 | |
| Alnylam Pharmaceuticals INC. | $30.00 | 2023 | |
| Boston Scientific Corporation | $29.70 | 2022 | |
| Kyowa Kirin, INC. | $20.74 | 2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $20.50 | 2020 | |
| Cormedix INC. | $18.31 | 2025 | Defencath |
| Glaxosmithkline, LLC. | $18.14 | 2020 | |
| Lilly USA, LLC | $16.24 | 2024 | Jardiance |
| Akebia Therapeutics INC | $15.58 | 2025 | Vafseo |
| Bard Peripheral Vascular, INC. | $13.04 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.